Frontotemporal Dementia

Targeting cellular senescence in tauopathies

Next steps in dementia biomarkers

Anti-HMGB1 agents for the treatment of Alzheimer’s disease

Tau fibrils versus tau oligomers in neurotoxicity and neurodegeneration

Tau oligomers trigger astrocyte senescence in tauopathy models

Biomarkers for frontotemporal dementia

Plasma NfL as a biomarker for frontotemporal dementia

Diagnostic tools for neurodegenerative disease

Dipeptide repeat proteins and the NLRP3 inflammasome in FTD

Next steps for research into the NLRP3 inflammasome in dementia

Understanding tau proteostasis using iPSC

The role of phosphorylated tau in clinical trials

Using phosphorylated tau as a diagnostic tool for Alzheimer’s disease

Understanding the relationship between MAPT mutations and disease pathology

MAPT mutations in frontotemporal dementia and Alzheimer’s

Exploring new topic areas with the Drug Discovery Institute